ADAR1 Capital Management, LLC and Daniel Schneeberger, who are identified as 10% owners of Rallybio Corp (NASDAQ:RLYB), collectively increased their holdings in the company's common stock through a series of transactions spanning May 13 and May 15, 2026. The total value of these insider acquisitions reached $1,112,976, with individual purchase prices varying between $13.7993 and $14.0 per share.
The timing of these reported purchases is noteworthy as the stock trades near its 52-week high of $15.31, following a substantial 411% appreciation over the past year. Despite this upward trajectory, analysis from InvestingPro suggests that, relative to its Fair Value estimate, Rallybio currently appears potentially overvalued.
Details of Insider Transactions
The buying pattern began on May 13, 2026. On this day, the reporting owners acquired 4,081 shares of Rallybio common stock at a weighted average price of $13.7993 per share. These specific shares were accumulated through several transactions, with reported individual prices ranging from $13.7700 to $13.8000.
Later on May 13, an additional acquisition was made involving 75,178 shares of RLYB at a uniform price of $14.0000 per share.
Further investment activity occurred two days later, on May 15, 2026. On this date, the reporting owners acquired 100 shares priced at $13.8000 per share and another tranche of 200 shares purchased at $13.9500 per share.
It is important to note that these reported securities are not held directly by the individuals; rather, they are indirectly owned through private investment funds and separately managed accounts overseen by ADAR1 Capital Management, LLC. Daniel Schneeberger, serving as the sole manager of ADAR1 Capital Management, LLC, may therefore be considered to have an indirect beneficial ownership stake in these securities. Both reporting parties explicitly disclaim any beneficial ownership of such shares, except for the extent of their direct pecuniary interest.
Recent Corporate Developments and Strategic Shifts
Beyond the reported stock purchases, Rallybio Corporation has been undergoing several significant corporate developments that signal major transitions within the biotechnology sector. One key development involves a substantial financial payout: Rallybio announced it will receive a $50 million termination fee after its planned merger with Candid Therapeutics was canceled. This fee is due to Candid terminating the original merger agreement to pursue an alternative deal involving UCB S.A., which entitles Rallybio to the payment under the terms of the initial pact.
On the scientific front, Rallybio reported promising results from a Phase 1 clinical trial for RLYB116, its subcutaneous C5 inhibitor. The data indicated complete and sustained inhibition of terminal complement when tested at a dose of 300 mg.
In terms of corporate structure, leadership saw a change with the departure of Rallybio’s Chief Medical Officer, Steven Ryder, M.D. His exit was accompanied by severance payments as detailed within a separation agreement. Previously, the company had publicized plans to acquire Candid Therapeutics in a merger valued at $505 million, a transaction that relied on private financing secured from multiple institutional investors.
These combined events-the insider buying activity, the positive clinical data for RLYB116, the receipt of the termination fee, and the leadership transition-underscore significant changes and milestones characterizing Rallybio’s recent operational timeline.